Issue 6
Jul 2022
Turn off MathJax
Article Contents
JOURNAL OF MECHANICAL ENGINEERING  > 2022  >  38(6): 558-562.
Zhao L,Su KS,Ye Z,et al.Research advances on the clinical characteristics and diagnosis and treatment of autoimmune disease-related ulcers[J].Chin J Burns Wounds,2022,38(6):558-562.DOI: 10.3760/cma.j.cn501120-20211019-00358.
Citation: Zhao L,Su KS,Ye Z,et al.Research advances on the clinical characteristics and diagnosis and treatment of autoimmune disease-related ulcers[J].Chin J Burns Wounds,2022,38(6):558-562.DOI: 10.3760/cma.j.cn501120-20211019-00358.
shu

Research advances on the clinical characteristics and diagnosis and treatment of autoimmune disease-related ulcers

doi: 10.3760/cma.j.cn501120-20211019-00358

  • Department of Rheumatology, the First Hospital of Jilin University, Changchun 130021, China

Funds:

Jilin Provincial Health Special Project JLSWSRCZX2020-0038

More Information
  • Corresponding author: Jiang Zhenyu, Email: jiangzhenyu2012@163.com
  • Received Date: 19 Oct 2021
    Available Online: 12 Aug 2022
  • Issue Publish Date: 20 Jun 2022
    Abstract
  • Studies have shown that autoimmune disease (AID)-related ulcers are disease complications that lead to serious poor prognosis such as infection and disability. It is difficult to make a clear diagnosis and there are contradictions between the applications of immunosuppressive therapy and anti-infectious therapy. Improper diagnosis and immunosuppressive therapy can easily delay the timing of anti-infectious therapy and surgery for patients, which bring adverse effects on the prognosis of patients. This paper reviews the concept, clinical characteristics and treatment suggestions of each subtype of AID-related ulcers, in order to provide more ideas for AID-related ulcers' clinical diagnosis and treatment.

     

    • FullText(HTML)
  • loading
    • References(51)
  • [1]
    SuzukiE,KyozukaH,NishidaT,et al.Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan[J].Mod Rheumatol,2009,19(4):447-451.DOI: 10.1007/s10165-009-0184-y.
    [2]
    LeaperDJ, SchultzG, CarvilleK, et al. Extending the TIME concept: what have we learned in the past 10 years?*[J]. Int Wound J, 2012,9 (Suppl 2):S1-19. DOI: 10.1111/j.1742-481X.2012.01097.x
    [3]
    BroughtonG2nd,JanisJE,AttingerCE.Wound healing: an overview[J].Plast Reconstr Surg,2006,117(7 Suppl):1e-S-32e-S.DOI: 10.1097/01.prs.0000222562.60260.f9.
    [4]
    MűzesG, SiposF. Primary immunodeficiency and autoimmune diseases[J]. Orv Hetil, 2018,159(23):908-918. DOI: 10.1556/650.2018.31064.
    [5]
    Amaya-UribeL,RojasM,AziziG,et al.Primary immunodeficiency and autoimmunity: a comprehensive review[J].J Autoimmun,2019,99:52-72.DOI: 10.1016/j.jaut.2019.01.011.
    [6]
    MaysJW,SarmadiM,MoutsopoulosNM.Oral manifestations of systemic autoimmune and inflammatory diseases: diagnosis and clinical management[J].J Evid Based Dent Pract,2012,12(3 Suppl):S265-282.DOI: 10.1016/S1532-3382(12)70051-9.
    [7]
    LoraV,CerroniL,CotaC.Skin manifestations of rheumatoid arthritis[J].G Ital Dermatol Venereol,2018,153(2):243-255.DOI: 10.23736/S0392-0488.18.05872-8.
    [8]
    GhoshSK, BandyopadhyayD, BiswasSK, et al. Mucocutaneous manifestations in patients with rheumatoid arthritis: a cross-sectional study from Eastern India[J]. Indian J Dermatol, 2017,62(4):411-417. DOI: 10.4103/ijd.IJD_260_17.
    [9]
    OlivéA,RiverosA,JuárezP,et al.Rheumatoid vasculitis: study of 41 cases[J].Med Clin (Barc),2020,155(3):126-129.DOI: 10.1016/j.medcli.2020.01.024.
    [10]
    Chua-AguileraCJ,MöllerB,YawalkarN.Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides[J].Clin Rev Allergy Immunol,2017,53(3):371-393.DOI: 10.1007/s12016-017-8632-5.
    [11]
    NarváezJ, Domingo-DomenechE, Gómez-VaqueroC, et al. Biological agents in the management of Felty's syndrome: a systematic review[J]. Semin Arthritis Rheum, 2012,41(5):658- 668. DOI: 10.1016/j.semarthrit.2011.08.008.
    [12]
    XueY,CohenJM,WrightNA,et al.Skin signs of rheumatoid arthritis and its therapy-induced cutaneous side effects[J].Am J Clin Dermatol,2016,17(2):147-162.DOI: 10.1007/s40257-015-0167-z.
    [13]
    SayahA,EnglishJC3rd.Rheumatoid arthritis: a review of the cutaneous manifestations[J].J Am Acad Dermatol,2005,53(2):191-209; quiz 210-212.DOI: 10.1016/j.jaad.2004.07.023.
    [14]
    SzekaneczZ,McInnesIB,SchettG,et al.Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases[J].Nat Rev Rheumatol,2021,17(10):585-595.DOI: 10.1038/s41584-021-00652-9.
    [15]
    GilliamJN,SontheimerRD.Distinctive cutaneous subsets in the spectrum of lupus erythematosus[J].J Am Acad Dermatol,1981,4(4):471-475.DOI: 10.1016/s0190-9622(81)80261-7.
    [16]
    SontheimerRD.The lexicon of cutaneous lupus erythematosus--a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus[J].Lupus,1997,6(2):84-95.DOI: 10.1177/096120339700600203.
    [17]
    NevskayaT,GambleMP,PopeJE.A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors[J].Clin Exp Rheumatol,2017,35(4):700-710.
    [18]
    KallasR,GoldmanD,PetriMA.Cutaneous vasculitis in SLE[J].Lupus Sci Med,2020,7(1):e000411.DOI: 10.1136/lupus-2020-000411.
    [19]
    CaproniM,VerdelliA.An update on the nomenclature for cutaneous vasculitis[J].Curr Opin Rheumatol,2019,31(1):46-52.DOI: 10.1097/BOR.0000000000000563.
    [20]
    JennetteJC,FalkRJ,BaconPA,et al.2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides[J].Arthritis Rheum,2013,65(1):1-11.DOI: 10.1002/art.37715.
    [21]
    ShiraiT,ShirotaY,FujiiH,et al.Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries[J].Scand J Rheumatol,2019,48(4):308-314.DOI: 10.1080/03009742.2018.1551965.
    [22]
    CriadoPR,MarquesGF,TCABMorita,et al.Epidemiological, clinical and laboratory profiles of cutaneous polyarteritis nodosa patients: report of 22 cases and literature review[J].Autoimmun Rev,2016,15(6):558-563.DOI: 10.1016/j.autrev.2016.02.010.
    [23]
    BulurI,OnderM.Behçet disease: new aspects[J].Clin Dermatol,2017,35(5):421-434.DOI: 10.1016/j.clindermatol.2017.06.004.
    [24]
    MatMC,SevimA,FreskoI,et al.Behçet's disease as a systemic disease[J].Clin Dermatol,2014,32(3):435-442.DOI: 10.1016/j.clindermatol.2013.11.012.
    [25]
    ObataS,KobayashiK,TodaM,et al.Genital ulcer of behçet disease localized in the vagina may lack pain, making it difficult to assess[J].Case Rep Rheumatol,2019,2019:2953676.DOI: 10.1155/2019/2953676.
    [26]
    BuntrockA,McNamaraM,TantoushH,et al.Worsening of behcet syndrome symptoms during pregnancy[J].S D Med,2021,74(3):112-114.
    [27]
    GeneraliE,CostanzoA,MainettiC,et al.Cutaneous and mucosal manifestations of Sjögren's syndrome[J].Clin Rev Allergy Immunol,2017,53(3):357-370.DOI: 10.1007/s12016-017-8639-y.
    [28]
    DamoiseauxJ.The diagnosis and classification of the cryoglobulinemic syndrome[J].Autoimmun Rev,2014,13(4/5):359-362.DOI: 10.1016/j.autrev.2014.01.027.
    [29]
    Ramos-CasalsM,Brito-ZerónP,SerorR,et al.Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements[J].Rheumatology (Oxford),2015,54(12):2230-2238.DOI: 10.1093/rheumatology/kev200.
    [30]
    CentalaS,ParkJH,GirnitaD.Sjogren's syndrome presenting with solely cutaneous features[J].Diagnostics (Basel),2021,11(7):1260.DOI: 10.3390/diagnostics11071260.
    [31]
    DeWaneME,WaldmanR,LuJ.Dermatomyositis: clinical features and pathogenesis[J].J Am Acad Dermatol,2020,82(2):267-281.DOI: 10.1016/j.jaad.2019.06.1309.
    [32]
    BogdanovI,KazandjievaJ,DarlenskiR,et al.Dermatomyositis: current concepts[J].Clin Dermatol,2018,36(4):450-458.DOI: 10.1016/j.clindermatol.2018.04.003.
    [33]
    KurtzmanDJB, VleugelsRA. Anti-melanoma differentiation- associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features[J].J Am Acad Dermatol,2018,78(4):776-785.DOI: 10.1016/j.jaad.2017.12.010.
    [34]
    NarangNS,Casciola-RosenL,LiSF,et al.Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation- associated gene 5 antibodies and interstitial lung disease[J].Arthritis Care Res (Hoboken),2015,67(5):667-672.DOI: 10.1002/acr.22498.
    [35]
    GuillevinL,HunscheE,DentonCP,et al.Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry[J].Clin Exp Rheumatol,2013,31(2 Suppl 76):S71-80.
    [36]
    MerkelPA,HerlynK,MartinRW,et al.Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon[J].Arthritis Rheum,2002,46(9):2410- 2420.DOI: 10.1002/art.10486.
    [37]
    PearsonDR,WerthVP,Pappas-TafferL.Systemic sclerosis: current concepts of skin and systemic manifestations[J].Clin Dermatol,2018,36(4):459-474.DOI: 10.1016/j.clindermatol.2018.04.004.
    [38]
    吴超,晋红中.坏疽性脓皮病的辅助检查及治疗[J].中华临床免疫和变态反应杂志,2019,13(4):301-305.DOI: 10.3969/j.issn.1673-8705.2019.04.010.
    [39]
    Julve-HerraizL,Villalba-FerrerF,García-CoretMJ,et al.Care and treatment of peristomal gangrenous pyoderma. A study of three cases[J].Enferm Clin (Engl Ed),2021,31(2):120-125.DOI: 10.1016/j.enfcli.2020.11.004.
    [40]
    唐锦明,祁少海,毛任翔,等.自身免疫性风湿病患者皮肤溃疡的临床特点与治疗策略[J/CD].中华损伤与修复杂志:电子版,2009,4(5):545-554.DOI: 10.3969/j.issn.1673-9450.2009.05.008.
    [41]
    VeselyMD.Getting under the skin: targeting cutaneous autoimmune disease[J].Yale J Biol Med,2020,93(1):197-206.
    [42]
    BusadaJT,CidlowskiJA.Mechanisms of glucocorticoid action during development[J].Curr Top Dev Biol,2017,125:147-170.DOI: 10.1016/bs.ctdb.2016.12.004.
    [43]
    Kowal-BieleckaO,FransenJ,AvouacJ,et al.Update of EULAR recommendations for the treatment of systemic sclerosis[J].Ann Rheum Dis,2017,76(8):1327-1339.DOI: 10.1136/annrheumdis-2016-209909.
    [44]
    StuckAE,MinderCE,FreyFJ.Risk of infectious complications in patients taking glucocorticosteroids[J].Rev Infect Dis,1989,11(6):954-963.DOI: 10.1093/clinids/11.6.954.
    [45]
    DerekE,DhanireddyK.Immunosuppression[J].Curr Opin Organ Transplant,2012,17(6):616-618.DOI: 10.1097/MOT.0b013e32835a7d3a.
    [46]
    SchuppeH,Richter-HintzD,StierleHE,et al.Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis[J].Rheumatology (Oxford),2000,39(1):105-106.DOI: 10.1093/rheumatology/39.1.105.
    [47]
    BettuzziT,JachietM,SbidianE,et al.Efficacy and safety of treatments in cutaneous polyarteritis nodosa: a French observational retrospective study[J].J Am Acad Dermatol,2022,86(5):1035-1041.DOI: 10.1016/j.jaad.2021.06.872.
    [48]
    GoldustM,HagstromEL,RathodD,et al.Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J].Expert Rev Clin Pharmacol,2020,13(2):157-161.DOI: 10.1080/17512433.2020.1709825.
    [49]
    OienRF,HåkanssonA,HansenBU.Leg ulcers in patients with rheumatoid arthritis--a prospective study of aetiology, wound healing and pain reduction after pinch grafting[J].Rheumatology (Oxford),2001,40(7):816-820.DOI: 10.1093/rheumatology/40.7.816.
    [50]
    HorwitzDA,FahmyTM,PiccirilloCA,et al.Rebalancing immune homeostasis to treat autoimmune diseases[J].Trends Immunol,2019,40(10):888-908.DOI: 10.1016/j.it.2019.08.003.
    [51]
    唐玉磊.褥疮护理新进展[J].中国老年保健医学,2007,5(4):143-144.DOI: 10.3969/j.issn.1672-4860-B.2007.04.091.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views(102) PDF downloads(0) Cited by()
    Proportional views
    Related

    Copyright © 2009《 石油钻探技术 》 All Rights Reserved.

    Address：North-Star Times Tower, No.8 Beichendong Road, Chaoyang District, Beijing, China China Pos：100101

    Tel：010-84988317，84988356，84988357 Fax：021-64253812 Email：syzt@vip.163.com

    Beijing public network security equipment 11010502036328　Beijing ICP backup 17033152

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return